Abbott India Partners With Novo Nordisk to Launch “Extensior” for Diabetes Care
Abbott India announced a new partnership with Novo Nordisk India on Friday to introduce a powerful tool for advanced diabetes management. Through this agreement, Abbott will market and sell Novo Nordisk’s semaglutide the molecule found in the well-known drug Ozempic under the brand name Extensior.
What is Extensior?
Extensior is a second brand of Ozempic, which is currently the world’s most prescribed GLP-1 receptor agonist (RA) molecule. According to an official exchange filing, Extensior is approved for adults with type 2 diabetes as an addition to diet and exercise.
As a GLP-1 RA, the treatment is recognized for providing a wide range of benefits for those living with this condition.
Key Benefits of Semaglutide
The active molecule in Extensior, semaglutide, has shown impressive results in clinical use, including:
- Significant reduction in HbA1c (blood sugar) levels.
- Notable weight-loss benefits.
- Lowered risk of heart and kidney related issues for people with type 2 diabetes.
In simple terms, these types of drugs mimic a natural hormone that slows digestion. This helps patients feel full for a longer period, making it easier to manage both weight and blood sugar.
Expanding Access in India
This announcement follows news from Zydus Lifesciences Ltd., which plans to launch its own semaglutide injection in India as soon as the current patent expires.
Abbott expects to make Extensior available to Indian patients soon as part of its growing portfolio of advanced diabetes solutions.
Addressing India’s Diabetes Challenge
The need for advanced treatment is urgent. “India is facing one of the world’s fastest growing diabetes burdens,” said Kartik Rajendran, Managing Director of Abbott India. “Addressing this challenge requires continuous innovation and strong partnerships.”
Recent health reports highlight the scale of the issue:
- Over 100 million people in India currently live with diabetes.
- This number is projected to rise to 150 million by 2050 a 50% increase.
- This surge is driven by rapid urbanization, an aging population, rising obesity, and lifestyle changes.
Also Read : Hyderabad Government to Introduce Pod Taxis to Solve Metro Connectivity Issues
